33 results about "Fluticasone propionate" patented technology

The invention discloses fluticasone propionate emulsifiable paste and a preparation method thereof. The preparation method of the fluticasone propionate emulsifiable paste comprises the following steps: S1, mixing liquid paraffin, isopropyl myristate and other auxiliaries, and heating to obtain an oil phase; s2, purified water, propylene glycol, disodium hydrogen phosphate dodecahydrate and other auxiliaries are mixed to obtain a water phase; and S3, adding the oil phase into the water phase, adding fluticasone propionate and the like after complete emulsification, uniformly stirring, and standing to obtain the cream. Compared with the prior art, the fluticasone propionate emulsifiable paste prepared by the invention is not easy to layer at high and low temperatures, and the obtained emulsifiable paste has better stability and is very beneficial to transportation, storage and the like of the product.

The invention discloses a method for detecting the granularity of raw materials in a suspension for fluticasone propionate aerosol inhalation, which comprises the following steps: heating the suspension for fluticasone propionate aerosol inhalation to be detected, and dissolving auxiliary materials to obtain a solution only containing the raw materials; adding the obtained solution into a heat-insulating dispersing agent, and dispersing again to prepare a sample suspension; and detecting the granularity of the fluticasone propionate in the obtained sample suspension by adopting a laser diffraction method. The invention provides a method suitable for detecting the granularity of raw materials in a suspension for fluticasone propionate aerosol inhalation, the suspension for fluticasone propionate aerosol inhalation is subjected to water bath heating, so that auxiliary materials are dissolved, it is guaranteed that only the fluticasone propionate raw material exists in a sample, the problem of interference of the auxiliary materials in detection of the granularity of the raw materials is avoided, and the detection accuracy of the granularity of the raw materials is improved. The accurate detection of the particle size distribution of the fluticasone propionate raw material in the suspension is realized.

The invention relates to biodegradable intranasal system for the sustained-release of fluticasone propionate in the intranasal cavity, said system comprising a biodegradable polyester matrix that comprises the fluticasone propionate as the active ingredient to be released in the intranasal cavity, wherein the polyester is selected from the list of poly(L,D-lactic acid) (PLA), poly(caprolactone) (PCL), their copolymers such as PLA-PCL, and mixtures thereof; and a method for preparing said system. The invention also relates to a kit comprising the system of the invention and the means of insertion of the system into the nasal cavity. The invention further relates to fluticasone propionate for use for treating chronic rhinitis or chronic sinusitis, wherein the fluticasone propionate is in a form suitable for administration in the nasal cavity by means of the biodegradable intranasal system of the invention.

The invention relates to the related technical field of measurement of the content of fluticasone propionate emulsifiable paste, in particular to a method for detecting the content of paste by adopting a high performance liquid chromatography, and particularly relates to a method for measuring the content of fluticasone propionate emulsifiable paste by adopting the high performance liquid chromatography, in particular to a method for detecting the content of fluticasone propionate emulsifiable paste by adopting the high performance liquid chromatography. Comprising the following steps: preparing a mobile phase from a diammonium hydrogen phosphate buffer solution (the pH value is 2.0-5.0), methanol and acetonitrile by adopting an octadecyl silane bonded silica gel column; and carrying out isocratic elution. According to the method disclosed by the invention, the diammonium hydrogen phosphate buffer solution-methanol-acetonitrile with a specific ratio is adopted as a mobile phase, and a chromatographic system in which an octadecyl silane bonded silica gel column and a guard column are connected in series is combined, so that the interference of oily auxiliary materials in a cream matrix is effectively eliminated, and the detection specificity and the separation effect are remarkably improved; besides, key chromatographic parameters such as column temperature, flow velocity and detection wavelength are optimized, and a scientific test sample pretreatment process is matched, so that the accuracy and reliability of a content measurement result are guaranteed.

The invention provides a method for detecting the content of fluticasone propionate cream. The method comprises the following steps: preparing an internal standard substance solution, preparing a test solution, preparing a reference substance solution, detecting and analyzing. According to the method, the cream is dispersed by heating in a water bath, the problem of uneven dissolution of the cream is solved, and the solution is centrifuged and filtered in a low-temperature environment of 6-10 DEG C to remove matrix impurities, so that the treatment efficiency of a cream sample can be improved, and the influence of personnel operation on a detection result can be effectively reduced; the accuracy of a detection result is improved. Besides, heptyl 4-hydroxybenzoate is selected as an internal standard substance, the retention behavior of heptyl 4-hydroxybenzoate is matched with that of fluticasone propionate, the solubility of heptyl 4-hydroxybenzoate in 65% ethanol is consistent, matrix adsorption and extraction errors can be effectively corrected, and the accuracy and reproducibility are remarkably superior to those of an existing method.

This invention discloses a compound ointment for protecting the nasal mucosa and repairing skin damage, and its preparation method, belonging to the field of pharmaceutical technology. The compound ointment is formulated with Sophora japonica fruit extract, erythromycin ointment, vitamin B6, levofloxacin hydrochloride tablets, loratadine tablets, fluticasone propionate nasal spray, sesame oil, and honey in specific weight proportions. The components work synergistically, providing protection for the nasal mucosa, treatment of rhinitis, reduction of cold air and external pollutant intrusion, and prevention of colds. It can also treat hemorrhoids, scars, eczema, and other skin damage, achieving "one medicine for multiple uses." This compound ointment has a stable dosage form, is convenient to use, has high utilization rate, high safety, and no obvious side effects, making it suitable for various populations and possessing good industrialization prospects.

The present invention relates to a biodegradable intranasal system for the sustained release of fluticasone propionate in the nasal cavity, said system comprising a biodegradable polyester matrix containing fluticasone propionate as an active ingredient to be released into the nasal cavity, the polyester being selected from the list of poly(L,D-lactic acid) (PLA), poly(caprolactone) (PCL), their copolymers such as PLA-PCL, and mixtures thereof, a biodegradable intranasal system, and a method for preparing said system. The present invention also relates to a kit comprising the system of the present invention and means for inserting the system into the nasal cavity. The present invention further relates to fluticasone propionate for use in treating chronic rhinitis or chronic sinusitis, which is in a form suitable for intranasal administration by the biodegradable intranasal system of the present invention.

A composition of fluticasone / linezolid-loaded nanodiamond / polyacrylonitrile nanofibers, consisting of: • Fluticasone propionate in a quantity of 25 mg to 100 mg; • Linezolid in a quantity of 25 mg to 100 mg; • Nanodiamonds dispersed in a concentration of approximately 1 mg / ml dimethylformamide (DMF); and • a polyacrylonitrile (PAN) polymer matrix prepared as a 10% w / v solution in DMF, wherein the drugs, nanodiamonds and PAN are uniformly combined to form an electrospinnable nanocomposite solution, and electrospinning is carried out under conditions suitable for producing nanofibers with controlled drug release, porosity and structural integrity for wound healing applications.

The invention discloses a photothermal stable fluticasone propionate emulsifiable paste preparation and a preparation process thereof, and relates to the technical field of external emulsifiable paste. Comprising the following steps: step 1, (1) adding isopropyl myristate and cetostearyl alcohol into liquid paraffin, mixing, heating and stirring to obtain an oil phase; (2) adding citric acid, sodium citrate, imidazolidinyl urea, a photo-thermal stabilizer and polyethylene glycol hexadecyl-octadecyl ether into deionized water, mixing, heating and stirring to obtain a water phase; (3) adding fluticasone propionate and propylene glycol into deionized water, heating and stirring to obtain a fluticasone propionate solution; and 2, adding the water phase into the oil phase, stirring, adding a fluticasone propionate solution, uniformly mixing, adding propyl hydroxybenzoate and methyl hydroxybenzoate, and standing at room temperature to obtain the fluticasone propionate emulsifiable paste preparation. The fluticasone propionate emulsifiable paste preparation prepared by the invention has good photo-thermal stability and meets the requirements of external emulsifiable paste.

The present application provides a kind of detection method of fluticasone propionate bulk drug particle size, the method is first used to high-power ultrasonic dispersion medium break dispersion medium molecule aggregation, then lower power ultrasonic dispersion system is stabilized, avoid dispersing agent itself aggregation to bulk drug particle is wrapped, form measurement error.In addition, by intermittent electric field, so that particle produces relative displacement or oscillation, while applying ultrasonic dissociation agglomerate, realize the complete wetting of bulk drug particle, stable dispersion and accurate detection, the method is lower to instrument requirement, can realize the accurate detection of strong hydrophobicity bulk drug particle size in the case where not increasing detection cost and detection time.

This invention relates to fluticasone propionate cream, belonging to the field of topical pharmaceutical preparations. By using a mixed solvent of hexanediol and propylene glycol, along with a composite stabilizer, this invention solves the problem in existing fluticasone propionate creams where inappropriate intradermal retention leads to insufficient therapeutic efficacy. Simultaneously, it ensures the stability of the cream; the cream of this invention remains stable under high temperature, high temperature, light, low temperature, and freeze-thaw conditions, with no significant increase in related substances. The preparation process of the fluticasone propionate cream of this invention is simple and suitable for industrial production.

This invention provides ACE2 expression inhibitors and their application in ACE2-mediated diseases. It uses human RXRα as a target protein for virtual drug screening and employs computer molecular docking technology to screen compounds with high affinity for the human RXRα receptor. Combined with cell experiments, it screens compounds that inhibit ACE2. The ACE2 expression inhibitors are at least one of ten drugs selected from ursolic acid, phlorizin, resveratrol, triamcinolone, budesonide, fluticasone propionate, vitamin D2, vitamin D3, calcitriol, and alfacalcidol. The ACE2 inhibitors screened by this invention can serve as targeted drugs for ACE2-mediated diseases, providing more drug options for the prevention or treatment of these diseases.

To provide a method for treating a disease.SOLUTION: Provided are potent soft corticosteroids, a pharmaceutical composition comprising the same, and a method for using the same as an anti-inflammatory agent. Also provided is a method for softening fluticasone propionate and similar corticosteroid and attaining a potent but safer alternative. Compounds which are equally as potent as fluticasone but safer than fluticasone, in particular S-fluoromethyl 17α-dichloroacetoxy-6α, 9α-difluoro-11β-hydroxy-16α-methyl-3-oxoandrosta-1,4-dien-17β-carbothioate is provided. Another compound of particular interest is 2-hydroxyethyl 17α-dichloroacetoxy-6α,9α-difluoro-11β-hydroxy-16β-methyl-3-oxoandrosta-1,4-diene-17β-carboxylate.SELECTED DRAWING: None

The application belongs to the technical field of mother liquor recycling, and particularly relates to a treatment method of fluticasone propionate mother liquor. The treatment method of fluticasone propionate mother liquor provided by the application first mixes the fluticasone propionate mother liquor and amine compounds to perform a Hofmann alkylation reaction, quenches fluorohalomethane under mild conditions by using the Hofmann alkylation reaction of the amine compounds, reduces the impurity of fluticasone propionate, and recovers fluticasone propionate with high purity and high recovery rate, so that the material is fully utilized, and the pollution of fluorohalomethane and steroid compounds (fluticasone propionate) to the environment is reduced.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a suspension for fluticasone propionate aerosol inhalation and a preparation method thereof. The suspension for fluticasone propionate aerosol inhalation provided by the invention is prepared from fluticasone propionate, isooctanol phosphate, a stabilizer, sodium dihydrogen phosphate, disodium hydrogen phosphate and an osmotic pressure regulator. According to the suspension for the fluticasone propionate aerosol inhalation provided by the invention, the foaming amount of the suspension is obviously reduced and the content uniformity of the suspension is improved by replacing the surfactant with the isooctanol phosphate, so that the product quality of the suspension for the fluticasone propionate aerosol inhalation is ensured.

The invention relates to the technical field of medicine refining, in particular to a process for reducing the content of genotoxic impurities in a fluticasone propionate raw material medicine. The process comprises the following steps: S1, reacting a compound I with bromofluoromethane in DMF (Dimethyl Formamide) under an alkaline condition, and adding an adsorbent into an obtained reaction solution; stirring at controlled temperature for a period of time, and filtering at low temperature to obtain fluticasone propionate filtrate; and S2, controlling the temperature at 0-10 DEG C, dropwise adding 1-1.5 mol of hydrochloric acid into the fluticasone propionate filtrate to adjust the pH value and deionized water, filtering, and drying to obtain the fluticasone propionate with reduced genotoxic impurity content. The process for reducing the content of the genotoxic impurities in the fluticasone propionate raw material medicine is simple and convenient to operate and low in cost, not only can reduce the harm of excessive bromofluoromethane to operators, but also greatly reduces the harm of the bromofluoromethane volatilized into the air to the environment, and is very suitable for large-scale industrial application.

This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

This invention relates to a method of treatment of asthma comprising a pro re nata (PRN) administration of a fixed-dose dry powder inhalation composition comprising fluticasone propionate and albuterol sulfate as a rescue medication in patients, wherein the fluticasone propionate is administered at a delivered dose of 22-59 mcg per inhalation and the albuterol sulfate is administered at a delivered dose of 92-124 mcg per inhalation, and wherein the treatment provides an improved baseline-adjusted postdose forced expiratory volume in one second (FEV1) area under the effect curve from time zero to 6 hours (AUEC0-6h) when compared to fluticasone propionate treatment and an improved baseline-adjusted trough FEV1 when compared to albuterol sulfate treatment.

This invention relates to the field of antiviral drug technology, disclosing fluticasone propionate and its application in the preparation of drugs against CHIKV and EEEV. Fluticasone propionate acts on the later stages of the CHIKV and EEEV life cycle. This invention is the first to demonstrate that fluticasone propionate has significant antiviral activity against CHIKV and EEEV, filling the gap in the lack of specific treatments for these two viruses. Furthermore, the fluticasone propionate of this invention is an already marketed drug; repurposing this existing drug can significantly shorten the research and development cycle and is expected to enable rapid clinical application.

The present invention relates to a method of treating asthma comprising administering as rescue medication a fixed-dose dry powder inhalation composition comprising fluticasone propionate and salbutamol sulfate in patients aged > 4 years on an as-needed (PRN) basis, wherein the fluticasone propionate is administered at a delivered dose of 22-59 micrograms per inhalation, the salbutamol sulfate is administered at a delivered dose of 92-124 micrograms per inhalation, and the treatment provides one or more of: an extended time to first severe clinical asthma exacerbation compared to salbutamol sulfate rescue treatment, a reduced total annualized systemic corticosteroid (SCS) exposure compared to salbutamol sulfate rescue treatment, a reduced annualized rate of severe clinical asthma exacerbations compared to salbutamol sulfate rescue treatment. Also provided is a fixed-dose dry powder inhalation composition and a dry powder inhaler for use in performing the method of the invention.

The present invention relates to a method of treating asthma, said method comprising the treatment of asthma at an age of > = 4 years to lt; a fixed dose of a dry powder inhalation composition comprising fluticasone propionate and salbutamol sulfate is administered as an emergency drug on demand (PRN) for a 18-year-old patient. Fixed dose dry powder inhalation compositions and dry powder inhalers for performing the methods of the invention are also provided.

The invention discloses a fluticasone propionate suspension nasal spray which is prepared by the following steps: on the basis of a prescription of fluticasone propionate micro powder, a suspending aid microcrystalline cellulose sodium carboxymethyl cellulose, an osmotic pressure regulator, a wetting agent and water, using a stabilizer methyl glucitol polyether-20 and hexanediol; the problem that the container adsorbs the fluticasone propionate micro powder in the preparation process is solved, and meanwhile degradation and particle size increase of the fluticasone propionate are effectively controlled.

The invention belongs to the technical field of drug detection, and relates to a UPLC analysis method for related substances of fluticasone propionate inhalation aerosol. Comprising the following steps: mixing acetonitrile and phosphoric acid water to prepare a diluent, adopting the diluent to dissolve fluticasone propionate inhalation aerosol to prepare a sample solution, adopting a chromatographic column taking octadecylsilane chemically bonded silica as a filling agent, taking the phosphoric acid water as a mobile phase A and taking acetonitrile as a mobile phase B, and carrying out gradient elution to obtain the fluticasone propionate inhalation aerosol. And performing UPLC detection on the sample solution according to a gradient elution program. Through the method, 12 impurities in the fluticasone propionate inhalation aerosol can be completely separated and accurately determined. The method is good in specificity and accurate in quantification, meanwhile, the mobile phase is simple and efficient to prepare, detection can be completed only in 13 min, the analysis time is greatly shortened, the solvent dosage is reduced, and the analysis cost is reduced.

The invention relates to a new topical nasal pharmaceutical composition for the treatment and prophylaxis of Rhinosinusitis (RS), comprising a homogeneous aqueous suspension with a therapeutically effective amount of the following well-known active ingredients: Rifamycin, an antibiotic and anti-inflammatory agent for topical or local use; fluticasone propionate, an anti-inflammatory agent for local use; optionally, oxymetazoline hydrochloride, a decongestant; and bacterial antigens, local immunostimulants; 0.9% saline solution, a vehicle; and pharmaceutically acceptable excipients q.s., which are formulated for topical administration via nasal spray. The combination of these compounds produces synergy, resulting in a greater local antibiotic, anti-inflammatory, decongestant and immunomodulatory effect at the specific site of action. Its effectiveness in chronic rhinosinusitis is particularly notable in low doses. So is its good tolerance, absence of adverse effects, and ease of application. No rebound congestion has been reported with prolonged use.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a high-stability fluticasone propionate suspension type cream and a preparation method thereof. The fluticasone propionate suspension type cream comprises fluticasone propionate, a liquid oil phase, a solid oil phase, an emulsifier, a humectant, an acid-base regulator, a preservative and a stabilizer, wherein the stabilizer is carbomer and / or xanthan gum. By exploring a product prescription and a process route, emulsion droplets and suspension type active ingredients are uniformly and lastingly wrapped in an emulsifiable paste system, the stability of the product can be obviously improved, key quality indexes such as rheology of the product are not obviously changed, meanwhile, the suspension type active ingredients can be kept in a uniform and stable distribution state for a long time, and the stability of the product is improved. And the cream product quality is further ensured.

The utility model relates to the technical field of cream packaging, provides an applicator for fluticasone propionate cream, and solves the technical problems that the fluticasone propionate cream is poor in flowability and poor in ball bottle using effect. The applicator comprises a bottle cap with a rolling body and a hard bottle body, a cream pushing assembly is arranged in the hard bottle body, and the applicator is characterized in that the cream pushing assembly comprises a pushing plate and a linear driving structure; the applicator further comprises an extrusion assembly. The extrusion assembly comprises an inner corrugated compression body, a perforated plate and an outer corrugated compression body, the inner corrugated compression body and the perforated plate are arranged between the lead screw and the bottle body in a sleeving mode, the upper end and the lower end of the inner corrugated compression body are fixedly connected with the push plate and the perforated plate respectively, and the linear driving structure is used for driving the push plate to move up and down along the bottle body.

A process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions may be used in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.

The invention relates to a buffered aqueous composition comprising fluticasone propionate dissolved therein in a concentration of at least 20 µg / mL, wherein the composition further comprises a saponin component selected from the group consisting of escin, glycyrrhizin, and Quillaja saponaria extract, a buffer adjusted to a pH of from 4 to 8; and the surfactant poloxamer P407 in a con- centration of from 2.5 to 15 %w / v. The invention further relates to the use of the composition in the treatment of inflammatory and / or allergic conditions of the human body.